Literature DB >> 23292598

The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term.

Yigit Akin1, Hakan Gulmez, Murat Ucar, Selcuk Yucel.   

Abstract

PURPOSE: To investigate if effects of the first single dose of tamsulosin 0.4 mg on uroflowmetry parameters would predict treatment response at the third month.
METHODS: Men over 40 years old with complaints of lower urinary tract symptoms associated with benign prostatic hyperplasia were studied with physical examination, urine and blood analysis, uroflowmetry (UFM), post-voiding residual urine volume (PVR), international prostate symptom score (IPSS), quality-of-life (QoL) index and transrectal prostate ultrasonography (TRUS), and patients with prostate cancer suspicion, past urinary surgery, urinary tract infection and neurologic diseases were excluded. UFM, PVR, IPSS, QoL were repeated at 6th hour of the first day, first month and third month of oral tamsulosin 0.4 mg treatment. All parameters were recorded as baseline, and changes in the UFM parameters, PVR, IPSS and QoL were evaluated in clinical visits.
RESULTS: As a total, 48 men (mean 60.17 ± 1.18 years) were recruited. There was a significant increase in maximum urine flow rate (Q (max)) and average urine flow rate (Q (ave)) and decrease in PVR from baseline with the first dose of tamsulosin as well as first and third month of treatment (p < 0.05). IPSS and QoL scores significantly improved at the first month in correlation with UFM parameters. Tamsulosin treatment was effective in 33 (68.7 %) patients at the first administration and 35 (72.9 %) at the third month. Positive predictive value and negative predictive value of Q (max) change at first dose for the third month response rate were 90.9 and 66.6 %, respectively.
CONCLUSIONS: The mid-term effectiveness of tamsulosin may be predicted by changes in UFM parameters achieved with its first dose.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23292598     DOI: 10.1007/s11255-012-0377-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

Review 1.  The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.

Authors:  D A Schwinn
Journal:  BJU Int       Date:  2001-09       Impact factor: 5.588

Review 2.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

3.  Are all alpha-blockers created the same?

Authors:  Jacques Irani
Journal:  Eur Urol       Date:  2006-01-06       Impact factor: 20.096

4.  Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score.

Authors:  S G Kang; C H Park; D K Kim; J K Park; S J Hong; B H Chung; C-S Kim; K-S Lee; J C Kim; J G Lee
Journal:  Int J Clin Pract       Date:  2011-06       Impact factor: 2.503

5.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.

Authors:  P Narayan; H Lepor
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

6.  Alpha blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2007

7.  Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study.

Authors:  M Wolzt; V Fabrizii; G T Dorner; G Zanaschka; P Leufkens; W J Krauwinkel; H G Eichler
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

8.  Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy.

Authors:  R Foglar; K Shibata; K Horie; A Hirasawa; G Tsujimoto
Journal:  Eur J Pharmacol       Date:  1995-01-16       Impact factor: 4.432

9.  Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management.

Authors:  K Muruganandham; Deepak Dubey; Rakesh Kapoor
Journal:  Indian J Urol       Date:  2007-10

10.  Various treatment options for benign prostatic hyperplasia: A current update.

Authors:  Alankar Shrivastava; Vipin B Gupta
Journal:  J Midlife Health       Date:  2012-01
View more
  6 in total

1.  Preliminary assessment of Neck Circumference in Benign Prostatic Hyperplasia in Patients with Metabolic Syndrome.

Authors:  Yigit Akin; Hakan Gulmez; Erhan Ates; Mehmet Gulum; Murat Savas
Journal:  Int Braz J Urol       Date:  2017 Jan-Feb       Impact factor: 1.541

Review 2.  Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence.

Authors:  Yuan-Hong Jiang; Hann-Chorng Kuo
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2017 Apr-Jun

3.  Predictive value of the immediate effect of first dose of tamsulosin on lower urinary tract symptoms improvement in benign prostatic hyperplasia patients.

Authors:  Ayman Salah Moussa; Rabie M Ibrahim; Mahmoud Shoukry ElAdawy; Ahmed M Ragheb; Ahmad A El-Dessoukey; Ahmed M Abdelbary; Ahmed Hassan Mohammed; Amr Massoud
Journal:  Urol Ann       Date:  2019 Jul-Sep

4.  Holmium laser enucleation of the prostate: surgical, functional, and quality-of-life outcomes upon extended follow-up.

Authors:  Ilter Alkan; Hakan Ozveri; Yigit Akin; Tumay Ipekci; Yusuf Alican
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

5.  Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study.

Authors:  Kyu-Sung Lee; Tag Keun Yoo; Limin Liao; Jianye Wang; Yao-Chi Chuang; Shih-Ping Liu; Romeo Chu; Budiwan Sumarsono
Journal:  BMC Urol       Date:  2017-11-21       Impact factor: 2.264

6.  Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study.

Authors:  Mehmet Demir; Yigit Akin; Kubra Asena Kapakin Terim; Mehmet Gulum; Evren Buyukfirat; Halil Ciftci; Ercan Yeni
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.